Clinical trials · New York
Leukemia clinical trials in New York
We’re tracking 183 recruiting leukemia studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06146257RecruitingPhase 1
Study of GLB-001 for Relapsed or Refractory AML or High-Risk MDS
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
Buffalo, New YorkAges 18 years+ - NCT06229912RecruitingPhase 2
Revumenib for leukemia with HOX gene changes
This trial tests an oral drug called revumenib (a menin inhibitor) for patients with acute leukemia that has returned or not responded to treatment, and whose leukemia has a specific HOX gene change. Revumenib aims to stop cancer growth by blocking a protein that helps leukemia cells survive.
New York, New YorkAges 12 years+ - NCT06297161Recruiting
A study of Bosulif for chronic myeloid leukemia
This study watches how well the medicine Bosulif works for adults with chronic myeloid leukemia in everyday medical practice. You can join if you’re already taking Bosulif or starting it soon, as long as you started within the last year.
New York, New YorkAges 20 years+ - NCT06297941RecruitingPhase 1
Study of REM-422 for AML or high-risk MDS
This trial tests an experimental oral medication called REM-422 for people with AML (a type of blood cancer) that has not responded to treatment or has come back, or for those with high-risk MDS. The goal is to see if it is safe and effective.
New York, New YorkAges 18 years+ - NCT06308588RecruitingPhase 1/Phase 2
Blinatumomab and asciminib for Ph+ ALL
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
The Bronx, New YorkAges 18 years+ - NCT06419634RecruitingPhase 1
New drug combo for returning AML or MDS
This study tests a new drug (BMS-986497) alone or combined with two other medicines (azacitidine and venetoclax) for people with AML or MDS that has not responded to or returned after prior treatments. The goal is to see if this combination can help control the disease.
New York, New YorkAges 18 years+ - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
New York, New YorkAges 18 years+ - NCT06561360RecruitingPhase 2
Comparing two treatments for hairy cell leukemia
This study tests whether a combination of targeted drugs (vemurafenib and obinutuzumab) works better than a standard chemo-immunotherapy combination (cladribine and rituximab) for people newly diagnosed with hairy cell leukemia. If you have the BRAF V600E mutation and meet blood count criteria, you may be eligible to join.
Uniondale, New YorkAges 18 years+ - NCT06697600Recruiting
Supporting decisions for older adults with AML and their caregivers
This study helps older adults with newly diagnosed acute myeloid leukemia (AML) and their caregivers make informed decisions about treatment. You and a caregiver (like a family member or friend) will get extra support to talk through your options.
Rochester, New YorkAges 60 years+ - NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
New York, New YorkAges 18 years+ - NCT06773208RecruitingPhase 2
Azacitidine and venetoclax for people with AML in remission
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
Rockville Centre, New YorkAges 18 years+ - NCT06918431RecruitingPhase 2
Erwinia asparaginase with chemo for new ALL or LBL
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
New York, New YorkAges 18–54 - NCT06969430RecruitingPhase 1/Phase 2
Debio 1562M for relapsed or refractory AML
This trial tests a new drug called Debio 1562M for people with AML that has not responded to treatment or has come back. It aims to see if the drug is safe and can help fight the leukemia.
Buffalo, New YorkAges 18 years+ - NCT07107126RecruitingPhase 1
Testing a new drug for relapsed AML or high-risk MDS
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
New York, New YorkAges 18 years+ - NCT07218510RecruitingPhase 2
Venetoclax, obinutuzumab, then epcoritamab for untreated CLL/SLL
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
New York, New YorkAges 18 years+ - NCT07223021RecruitingPhase 3
Fludarabine dosing study for B-cell ALL
This study tests a different dose of the chemotherapy drug fludarabine before CAR T-cell therapy (tisagenlecleucel) for children and young adults with B-cell acute lymphoblastic leukemia. The goal is to see if the new dose works better at helping the body accept the CAR T cells while keeping side effects manageable.
New York, New YorkAges 1 year+ - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Buffalo, New YorkAges 18–39 - NCT02560883Recruiting
Hairy cell leukemia patient data registry
This registry collects information about people with classic and variant hairy cell leukemia. It helps doctors learn from real-world patient data and may improve future care.
Rochester, New YorkAges 18 years+ - NCT07283094RecruitingPhase 1
FHD-286 with decitabine and venetoclax for AML
This early-phase trial tests a new study drug called FHD-286 combined with two standard AML medicines (decitabine and venetoclax). It is for people with a high-risk type of AML that is either newly diagnosed (and you cannot have strong chemotherapy) or has come back after one prior treatment.
The Bronx, New YorkAges 18 years+ - NCT07392242RecruitingPhase 2
Ivosidenib, azacitidine, and venetoclax for acute myeloid leukemia
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
Commack, New YorkAges 60 years+ - NCT01311258Recruiting
Tracking leftover cancer cells in AML or high-risk MDS
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
Rochester, New YorkAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Stony Brook, New YorkAges Any age - NCT04925479RecruitingPhase 1/Phase 2
Testing asciminib dosing and safety for teen CML patients
This early-phase study tests the right dose and safety of asciminib in children and teens with chronic myeloid leukemia (CML). It may help if your current or last CML medicine (a TKI) did not work well or caused side effects.
New York, New YorkAges 1–17 - NCT02646839Enrolling by invitationPhase 2
Testing a gene-matched transplant approach for childhood leukemia
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Valhalla, New YorkAges Up to 21 years
Leukemia trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting leukemia studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Memorial Sloan Kettering Commack · 3 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- Memorial Sloan Kettering Westchester · 2 studies
- Roswell Park Cancer Institute · 2 studies
- Roswell Park Comprehensive Cancer Center · 2 studies
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Leukemia trials in other states
Common questions
- Are there leukemia clinical trials in New York?
- Yes. We're currently tracking 183 recruiting leukemia studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.